Operation Brain Trauma Therapy

Operation Brain Trauma Therapy (OBTT) is a multisite research consortium composed of investigators from several internationally recognized research centers that was created  in 2011 to respond to the need for novel therapies and biomarkers in traumatic brain injury (TBI). OBTT was designed to serve as a high-throughput therapy screening research consortium that identifies the most promising therapies and compares them across a spectrum of the state-of-the-art models and injury levels. The most promising therapies are moved up the phylogenetic scale. OBTT then recommends agents that are either U.S. Food and Drug Administration (FDA) approved for other uses, or are in clinical development that are found to be effective across models for rapid clinical translation to the US Army. OBTT is structured to allow a direct comparison of therapies across TBI models in multiple centers. It also includes a comparison of therapies across highly relevant combat casualty care scenarios. OBTT is supported by the United States Army grant W81XWH-10-1-0623.

OBTT Investigators from left to right:
 Frank Tortella, Kevin Wang, John Povilshock, Patrick Kochanek, C. Edward Dixon, Deborah Shear, Kara Schmid, Helen Bramlett, W. Dalton Deitrich, and Ronald Hayes.

OBTT is composed of six sites:

The Safar Center for Resuscitation Research, University of Pittsburgh School of Medicine                     
Patrick Kochanek, MD, Over All Primary Investigator                                                                                      C. Edward Dixon, PhD, Co-Director and Site Primary Investigator
The Miami Project to Cure Paralysis, University of Miami School of Medicine
W. Dalton Deitrich, PhD, Site Primary Investigator                                                             
Helen Bramlett, PhD 
The Neuroprotection Program at Walter Reed Army Institute of Research  
Frank Tortella,MD, Site Primary Investigator 
Deborah Shear,PhD
MAJ. Kara Schmid, PhD
Virginia Commonwealth University 
John Povilshock, PhD, Site Primary Investigator 
Banyon Biomarkers Inc., Alachua,Florida
Biomarker core directed by
Ronald Hayes, PhD
Center for Neroproteomics & Biomarkers Research, University of Florida
Kevin K.W. Wang, PhD